These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22046106)

  • 21. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
    Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
    Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beat-to-beat corrected QT analysis detects corrected QT prolongation in 50 consecutive telemetry-monitored patients.
    Davidson JE; Agan D; Ballard DL; Truong HT; Bridgen CM; Rubino S; Sikand H; Stein J
    J Cardiovasc Nurs; 2013; 28(6):584-90. PubMed ID: 22990234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Generation Antipsychotic Drugs and QTc Interval Prolongation.
    Vieweg WV
    Prim Care Companion J Clin Psychiatry; 2003 Oct; 5(5):205-215. PubMed ID: 15213787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperglycemia and subsequent torsades de pointes with marked QT prolongation during refeeding.
    Nakashima T; Kubota T; Takasugi N; Kitagawa Y; Yoshida T; Ushikoshi H; Kawasaki M; Nishigaki K; Ogura S; Minatoguchi S
    Nutrition; 2017 Jan; 33():145-148. PubMed ID: 27544004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous Ondansetron and the QT Interval in Adult Emergency Department Patients: An Observational Study.
    Moffett PM; Cartwright L; Grossart EA; O'Keefe D; Kang CS
    Acad Emerg Med; 2016 Jan; 23(1):102-5. PubMed ID: 26720490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
    Muzyk AJ; Rayfield A; Revollo JY; Heinz H; Gagliardi JP
    Drug Saf; 2012 Jul; 35(7):547-53. PubMed ID: 22702639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long QTc and torsades de pointes in human immunodeficiency virus disease.
    Kocheril AG; Bokhari SA; Batsford WP; Sinusas AJ
    Pacing Clin Electrophysiol; 1997 Nov; 20(11):2810-6. PubMed ID: 9392812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ondansetron induced
    Patel E; Rosemond D; Afzal A
    Clin Case Rep; 2019 Aug; 7(8):1557-1558. PubMed ID: 31428390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The incidence of torsades de pointes with peri-operative low-dose ondansetron administration.
    Nuttall GA; Voogd SC; Danke H; Warner PA; Oyen LJ; Marienau MS; Ackerman MJ
    Pharmacotherapy; 2022 Apr; 42(4):292-297. PubMed ID: 35124842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
    Lawrence KR; Nasraway SA
    Pharmacotherapy; 1997; 17(3):531-7. PubMed ID: 9165555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of QT prolongation after administration of a 24-mg bimodal-release ondansetron pill (RHB-102).
    Miller J; House S; Lovato L; Meltzer A; Hahn B; Avarello J; Plasse T; Kalfus I; Fathi R; Silverman R
    Am J Emerg Med; 2021 May; 43():205-209. PubMed ID: 32139212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population?
    Nuttall GA; Eckerman KM; Jacob KA; Pawlaski EM; Wigersma SK; Marienau ME; Oliver WC; Narr BJ; Ackerman MJ
    Anesthesiology; 2007 Oct; 107(4):531-6. PubMed ID: 17893447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia.
    Doggrell SA; Hancox JC
    Expert Opin Drug Saf; 2013 May; 12(3):421-31. PubMed ID: 23578248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Intravenous Ondansetron on the QT Interval of Patients' Electrocardiograms.
    Krammes SK; Jacobs T; Clark JM; Lutes RE
    Pediatr Emerg Care; 2018 Jan; 34(1):38-41. PubMed ID: 27261956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of oral ondansetron on QT interval in children with acute gastroenteritis; a retrospective observational study.
    Yang H; Jeon W; Ko Y; Jeong S; Lee J
    BMC Pediatr; 2021 Nov; 21(1):501. PubMed ID: 34758763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QTc prolongation, torsades de pointes, and psychotropic medications.
    Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
    Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
    Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
    Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
    Haddad PM; Anderson IM
    Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and determinants of QT interval prolongation in medical inpatients.
    Pasquier M; Pantet O; Hugli O; Pruvot E; Buclin T; Waeber G; Aujesky D
    Intern Med J; 2012 Aug; 42(8):933-40. PubMed ID: 21299787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.